> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Travere Therapeutics Plans Filspari sNDA
- URL: https://www.fdaweb.com/travere-therapeutics-plans-filspari-snda/
- Published: 2025-02-12T12:00:00.000Z
- Updated: 2026-09-14T14:53:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158644

Travere Therapeutics says it plans to submit an sNDA to FDA for traditional approval of a new indication for Filspari (sparsentan) to treat focal segmental glomerulosclerosis. A company [statement](https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-submit-snda-filsparir-sparsentan-fsgs?ref=fdaweb.com) says the sNDA will be based on data from the Phase 3 DUPLEX and Phase 2 DUET studies. It is to be submitted near the end of the first quarter of 2025, Travere says.

Filspari is currently indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.